Digital Diagnostics , the leading global platform for healthcare solutions enhanced with independent AI technologies, has announced the acquisition of 3Derm Systems, a medical company, "3Derm Systems", headquartered in Boston, Massachusetts. As such, it becomes the sole owner of independent AI healthcare software tools that are licensed de novo from the US Food and Drug Administration. This resulted in adding Saudi Arabia and the UAE to the list of emerging markets in which it will operate.
Autonomous artificial intelligence techniques allow the computer – not the doctor – to make appropriate medical decisions, providing patients with the opportunity to obtain a diagnosis of serious cases, as well as choosing when and where to receive appropriate health care quickly and easily. The company says that trials have shown improved outcomes for patients, especially those who are underserved, thanks to their immediate diagnosis of healthcare providers.
While we are living in a difficult health situation in the world due to the repercussions of the Corona virus, these technologies are the ideal way to diagnose patients' cases without delay.
This acquisition of 3Derm Systems solidifies Digital Diagnostics as a leader in AI healthcare solutions.
The acquisition will also help the company roll out standalone artificial intelligence systems that specialize in diagnosing skin cancer.
This will move the company into a completely new niche medical field. The new tool makes early diagnoses of medically dangerous cases, thus reducing the risk of disease exacerbation, and ensuring improved patient outcomes.
IDx-DR technology is the company's flagship product, and it is one of the first systems supported by independent artificial intelligence technologies to be certified de novo from the US Food and Drug Administration. According to the company, it diagnoses diseases such as diabetic retinopathy and diabetic macular edema. It will also enhance its capabilities with the first autonomous AI solutions from 3Derm Systems awarded by the US Food and Drug Administration (FDA) Dermatology Specific Certification, for its ability to diagnose melanoma, squamous cell carcinoma, and basal cell carcinoma.
Saudi Arabia is the next destination for Digital Diagnostics
The Kingdom of Saudi Arabia places a lot of attention on digital early diagnosis products for diabetes and its associated medical complications. According to the company, projections show that 18.3% of the adult population in the Kingdom is at risk of developing type 1 diabetes and related medical complications. Diabetic retinopathy is one of the most prominent complications of diabetes affecting the eye, and it is expected to affect 33.7% of diabetes patients in the Kingdom, amid expectations that the costs of treating diabetes in the Kingdom will reach about $ 870 million on an annual basis.
Early detection of diabetic retinopathy and diabetic myopathy, using independent and AI-based diagnostic tools from Digital Diagnostics, plays an important role in diagnosing and treating early-stage patients.
The technology also contributes to reducing the costs of treating diabetes and related medical complications in early diagnosis of diseases.
Digital Diagnostics from an ophthalmologist to all the world
Digital Diagnostics was founded in 2010 by Michael Abramoff, an ophthalmologist, practicing retina specialist, fellowship, neuroscientist and computer engineer who developed a unique, patented methodology that relies on biomarkers to build algorithms to perform complex tasks. These algorithms are integrated into easy-to-use systems, so that computers can make clinical clinical decisions in real time.
Commenting on the matter, Dr. Michael Abramoff, Founder, Managing Director and CEO of Digital Diagnostics, said: “We face a great deal of unnecessary suffering due to treatable illnesses. This is more frequent among the population who lack equitable access to health care services, especially for professionals. Healthcare physicians and other front-line service providers can use our standalone systems to make real-time diagnoses for severe cases, and to speed up referrals of patients to specialists, improving patient outcomes in the long term. Thanks to the advanced position of the region in terms of relying on international medical technologies, we are all confident in the ability of these modern software solutions enhanced by independent artificial intelligence to occupy the first place for health care officials in various parts of the country, and the Gulf region more broadly.
Abramov continued: “Statistics show that approximately 20% of the population of the Kingdom of Saudi Arabia has diabetes, and a third of individuals over the age of 40 suffer from diabetic retinopathy, which is a medical complication that can be detected quickly and efficiently using our artificial intelligence-supported technologies. And the benefits of artificial intelligence are not limited to this for healthcare providers interested in advanced technological tools. Our acquisition of 3Derm will enhance our ability to provide AI-enabled tools for early detection of skin cancer, which will constitute a new way to ensure that the required levels of care are provided more efficiently and based on the best innovative tools. ”
High-resolution images contribute to an immediate and fast diagnosis
The AI-assisted IDx-DR technologies from Digital Diagnostics and 3Derm Spot from 3Derm Systems rely on high-quality images of the eyes and skin, accompanied by artificial intelligence technologies, to make the diagnosis instantly and without the need for specialized operating personnel.
The company's products are used in a large number of the most prestigious health systems in the world, including the United States of America, Poland, Austria, and the Netherlands.
The company has also previously collaborated with regulators and healthcare institutions to enable reliance on independent AI systems in the healthcare sector.
John Bertrand, CEO of Digital Diagnostics, commented: “We are pleased that government agencies are beginning to realize the efficiency of diagnostic systems supported by autonomous artificial intelligence and their ability to improve the delivery of health care services. By working with physicians and other health care providers, we will reach more patients, diagnose diseases sooner, and meet the care needs of patients at risk. This enables specialists to perform their tasks optimally, prevent blindness and treat skin cancer.
You can learn about some of the important achievements of Digital Diagnostics:
- April 2013: Class IIa CE certified
- 2018: IDx-DR technology obtained Dermatology Specific System certification from the US Food and Drug Administration.
- 2018: The US Food and Drug Administration for the first time licenses the de novo standard for one of the systems enhanced with autonomous AI technologies.
- June 2018: Introduced interim I CPT code 92250-TC, intended for artificial intelligence to diagnose diabetic retinopathy and diabetic macular edema.
- May 2019: The American Medical Association creates CPT Class I with code X9225, intended for autonomous artificial intelligence, to be implemented in January 2021.
- 2019: The American Diabetes Association updates its standard of diabetes care to include autonomous AI, specific to diabetic retinopathy.
- January 2020: Three Derm Spot achieved the Specific Dermatological System Certification from the US Food and Drug Administration.
- August 3, 2020: The Centers for Medicare and Medicaid Services of the USA announces that Medicare will cover costs for CPT code 9225X.
- August 2020: The company announces the acquisition of 3Derm Systems, paving the way for the 3Derm Spot to be available to the EMEA market.
List of markets where IDx-DR technology is available:
- Netherlands : The Netherlands witnessed the first implementation of IDx-DR technology around the world under Class IIa CE certification.
- Poland : Voivodeship has adopted IDx-DR technology for eye examinations for all diabetics.
- Austria : IDx-DR deployed to several outpatient diabetes clinics in Vienna. The company is working as a prominent university to obtain national compensation for IDx-DR.
- Germany : The company has completed a pilot phase, and is working with insurance companies to introduce IDx-DR technology as a healthcare service whose costs can be covered.
- List of emerging markets, which includes the Kingdom of Saudi Arabia and the United Arab Emirates.
- BANGLADESH : The company and Orbis International are collaborating to enable artificial intelligence to improve the productivity of eye specialists to reduce avoidable blindness.
It is noteworthy that the launch of Digital Diagnostics of its technology in the Kingdom of Saudi Arabia will contribute more to moving medical diagnostics to a new direction.